Global Specialty Control Plasma Market is valued at approximately USD 9.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.29% over the forecast period 2024-2032. Specialty control plasma is an essential laboratory product utilized in clinical diagnostics to ensure the precision and reliability of coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT). This control plasma, derived from human or animal sources, is meticulously formulated to contain known levels of clotting factors, serving as a benchmark to validate the performance of coagulation assays. This enables laboratories to identify variations in test outcomes, thereby maintaining consistent and high-quality diagnostic results across various testing platforms.

The Global Specialty Control Plasma Market growth is propelled by significant investment in research and development activities, escalating demand for plasma-derived drugs globally, and the rising geriatric population. The increased prevalence of infectious diseases worldwide, coupled with advances in biotechnology and the expanding application of plasma-derived therapies, also drives the market. Additionally, the rapid growth of the healthcare sector and heightened consumer awareness further bolster the demand for specialty control plasma. However, high cost of associated with plasma-derived products is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America is poised to hold a substantial share of the specialty control plasma market, primarily due to the region's advanced development and manufacturing capabilities. The presence of major industry players in the USA and Canada offers significant growth opportunities. Meanwhile, the Asia Pacific region is expected to capture a considerable market share, driven by advancements in medical technology and the increasing prevalence of chronic disorders. The growing demand for plasma-delivered therapies and heightened awareness about plasma donation further stimulate market growth in this region.

Major market players included in this report are:
Precision BioLogic Incorporated
Baxter BioScience
Grifols S.A.
Shire Plc.
VitroPharma
Kedrion S.p.A.
China Biologic Products (Shandong Taibang)
Biotest AG
Sanquin
Talecris Biotherapeutics
SK Plasma Co.
CSL Ltd.
Octapharma AG
Cerus Corp.
Hemasoft
The detailed segments and sub-segments of the market are explained below:
By Type:
Factor VIII Concentrate
Factor IX Concentrate
Immunoglobulins
Others
By Application:
Coagulation Disorders
Immunodeficiency Diseases
Hypogammaglobulinemia
By End User:
Hospitals
Diagnostic Laboratories
Clinics
Others
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
RoLA
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market